title: Regulatory network of mitomycin C action in human colon cancer cells.
abstract: A network composed of activation and inactivation pathways to regulate mitomycin C (MMC) action is suggested to exist in human cancer cells. COLO201 colon cancer cells were stably transfected with human NQO1 cDNA that encodes NAD(P)H:quinone oxidoreductase (DT-diaphorase, DTD), and a clonal cell line with about 57-fold elevated DTD activity was obtained. Northern analysis revealed that expression of the NADPH:cytochrome P450 reductase (P450 reductase) gene was decreased in the transfectant, COLO201/NQO1, associated with the increase of NQO1 expression. Biochemical characterization of the cells showed a significant increase of the glutathione (GSH) content concomitantly with the decrease of the P450 reductase activity. As a result of these coordinated modulations, sensitivity of COLO201/NQO1 to MMC was not increased as compared to the parent cells. Analyses of inhibition by specific inhibitors of DTD, P450 reductase and glutathione S-transferase (GST) in 5 human colon cancer cell lines including the transfectant showed that DTD and P450 reductase play significant roles in MMC activation in cells with sufficiently high DTD activity and with marginal DTD activity, respectively. In contrast, GST appeared to participate in MMC inactivation in cells with a high level of GST activity. These results indicated that DTD, P450 reductase, GSH and GST may act together compensatively or competitively, depending on their levels in cells, to determine the cellular sensitivity to MMC.
authors.affiliation: Department of Biochemistry and Biophysics, Research Institute for Radiation Biology and Medicine, Hiroshima.
authors.forename: K
authors.initials: K
authors.lastname: Suzuki
authors.forename: W
authors.initials: W
authors.lastname: Yamamoto
authors.forename: J S
authors.initials: JS
authors.lastname: Park
authors.forename: H
authors.initials: H
authors.lastname: Hanaoka
authors.forename: R
authors.initials: R
authors.lastname: Okamoto
authors.forename: Y
authors.initials: Y
authors.lastname: Kirihara
authors.forename: T
authors.initials: T
authors.lastname: Yorishima
authors.forename: T
authors.initials: T
authors.lastname: Okamura
authors.forename: T
authors.initials: T
authors.lastname: Kumazaki
authors.forename: M
authors.initials: M
authors.lastname: Nishiyama
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018076:DNA, Complementary / Q000235:genetics*; D004354:Drug Screening Assays, Antitumor; D005815:Genetic Code; D005982:Glutathione Transferase / Q000378:metabolism; D006801:Humans; D016685:Mitomycin / Q000627:therapeutic use*; D016660:NAD(P)H Dehydrogenase (Quinone) / Q000235:genetics*; D009251:NADPH-Ferrihemoprotein Reductase / Q000378:metabolism; D014162:Transfection; D014407:Tumor Cells, Cultured
chemical_list: D000903:Antibiotics, Antineoplastic; D018076:DNA, Complementary; D016685:Mitomycin; D009251:NADPH-Ferrihemoprotein Reductase; D016660:NAD(P)H Dehydrogenase (Quinone); D005982:Glutathione Transferase